CounterPath, Corp. (NASDAQ:CPAH) (TSE:CCV)’s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.00 and traded as high as $1.45. CounterPath shares last traded at $1.44, with a volume of 11,509 shares traded.
Separately, ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st.
The company has a 50-day simple moving average of $1.52. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.84 and a current ratio of 0.84.
An institutional investor recently bought a new position in CounterPath stock. Wedbush Securities Inc. acquired a new position in CounterPath, Corp. (NASDAQ:CPAH) (TSE:CCV) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 26,000 shares of the software maker’s stock, valued at approximately $43,000. Wedbush Securities Inc. owned approximately 0.44% of CounterPath as of its most recent SEC filing. Institutional investors and hedge funds own 5.61% of the company’s stock.
CounterPath Company Profile (NASDAQ:CPAH)
CounterPath Corporation designs, develops, and sells software and services that enable enterprises and telecommunication service providers to deliver unified communications services over Internet protocol based networks in North America and internationally. Its products include Bria softphone suite, which enables consumers and business users to make voice over Internet protocol (VoIP) audio and video calls, send instant messages, manage their presence, share their screen, and collaborate with other users using desktop computers and laptops, smartphones, and tablets; and X-Lite, a standards-based VoIP softphone application that runs on desktop computers.
Featured Story: What are the FAANG Stocks?
Receive News & Ratings for CounterPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CounterPath and related companies with MarketBeat.com's FREE daily email newsletter.